Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nepal Healthcare Times.
Press releases published on August 19, 2025
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, …
Ajax Therapeutics Appoints David Waller, PhD, as Senior Vice President and Head of CMC
NEW YORK and CAMBRIDGE, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation Janus Kinase (JAK) inhibitors for patients with myeloproliferative neoplasms, today announced the appointment …
COUR Pharma Doses First Patient in Clinical Trial Evaluating CNP-103 in People Recently Diagnosed with Type 1 Diabetes
CHICAGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies to treat autoimmune diseases, today announced that the first patient has been dosed in the Phase 1b/2a …
BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic’s IzoView Device
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging …
Milestone® Pharmaceuticals to Present at Upcoming Conferences
MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, to take place …
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window -First-in-human trial of ALX2004 builds …
ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders
UNIONDALE, NY, Aug. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that it filed a definitive proxy statement (“DEF 14A”) …
Global Central Lab Services Market to Reach USD 8.18 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global Central Lab Services Market, valued at US$5.64 billion in 2024, stood at US$5.97 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a …
Aveanna to Participate at the Deutsche Bank Healthcare Summit
ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Deutsche Bank Healthcare Summit in New York on September 10, 2025. Management will host 1x1 …
Global Negative Pressure Wound Therapy Market to Surpass USD 3.84 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The global negative pressure wound therapy market, valued at US$2.59 billion in 2024, stood at US$2.76 billion in 2025 and is projected to advance at a resilient CAGR of 6.9% from 2025 to 2030, …
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage …
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth
WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today …
Angitia Biopharmaceuticals to Present Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025
- Angitia abstracts selected for two oral presentations and three posters - Angitia collaborator also selected for poster presentation WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology …
Memo Therapeutics AG Publishes Phase I Safety, Tolerability, and Pharmacokinetics Study for Neutralizing Antibody Targeting BKPyV Infection in Clinical and Translational Science
First-in-human, Phase I, randomized, placebo-controlled study, successfully demonstrated safety and tolerability of potravitug in healthy volunteers The Company recently announced the results from its Phase II placebo-controlled clinical trial of …
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial …
Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy
Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment.1-4 Initial cases have now been performed in Japan. WAYNE, Pa., Aug. 19, 2025 (GLOBE …
Merakris Therapeutics Receives USPTO Notice of Allowance for Foundational Patent Supporting MTX-001 Biologic Drug Platform
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics today announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent No. US-2022/0133806 A1, covering the company's …
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy …
ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and subgroup analysis from its recent Phase 3 COMPETE trial will be …